Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome

Nefrologia (Engl Ed). 2018 Jul-Aug;38(4):448-450. doi: 10.1016/j.nefro.2017.10.001. Epub 2017 Dec 6.

[Article in English, Spanish]

Authors

Aysegul Oruc¹, Yavuz Ayar², Berna Aytac Vuruskan³, Abdulmecit Yildiz², Nimet Aktas⁴, Mahmut Yavuz², Mustafa Gullulu², Kamil Dilek², Alparslan Ersoy²

Affiliations

¹ Department of Internal Medicine, Division of Nephrology, Uludağ University Medical School, Bursa, Turkey. Electronic address: aysegul@uludag.edu.tr.
² Department of Internal Medicine, Division of Nephrology, Uludağ University Medical School, Bursa, Turkey.
³ Department of Pathology, Uludağ University Medical School, Bursa, Turkey.
⁴ Cekirge State Hospital, Department of Nephrology, Bursa, Turkey.

PMID: 29221881
DOI: 10.1016/j.nefro.2017.10.001

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Atypical Hemolytic Uremic Syndrome / complications
Atypical Hemolytic Uremic Syndrome / drug therapy*
Chemical and Drug Induced Liver Injury / etiology*
Humans
Male

Substances

Antibodies, Monoclonal, Humanized
eculizumab